Kevin M. Gray, MD
Medical University of South Carolina
Dept. of Psychiatry & Behavioral Sciences
The purpose of this study was to measure any change in the rate of cigarette smoking among participants in the CTN-0028 (at the LRADAC site only). The hypothesis is that OROS-MPH treatment for ADHD among adolescents with comorbid ADHD, SUD, and nicotine dependence will not increase the rate of cigarette smoking. The study will compare self-reported smoking rate and urine cotinine semi-quantitative levels in adolescents receiving OROS-MPH vs. those receiving placebo to test the hypothesis above.
Baseline (pre-treatment) cigarette smoking was positively correlated with cannabis use. Negligible decline in cigarette smoking during treatment for non-nicotine SUD was observed in both medication groups. Regular cigarette and cannabis users at baseline who reduced their cannabis use by >50% also reduced cigarette smoking.
Results Article: Gray KM, Riggs PD, Min SJ,et al. Cigarette and Cannabis Use Trajectories among Adolescents in Treatment for Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders. Drug and Alcohol Dependence 2011;117(2-3):242-247. [get article]
- CTN-0028: Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents with Substance Use Disorders
All Participating Nodes: